Type 2 Diabetes: Recent Guidelines for Cardiovascular Risk Reduction

Recent Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes have been established to help control the risks associated with this chronic condition. These guidelines are focused on reducing the risk of heart attack, stroke, and other cardiovascular diseases (CVDs) through lifestyle changes and medications.

The American Diabetes Association (ADA) has released a statement that recommends lifestyle changes as the basis for CVD risk reduction in patients with Type 2 diabetes. This includes making healthy food choices, increasing physical activity, and losing weight if needed. The statement also recommends strategies for preventing or delaying complications, including working closely with one’s health care team and managing blood sugar levels.

Other key components of the ADA guidelines include regular screening for high blood pressure, cholesterol, and kidney disease; taking aspirin or other antiplatelet medication as recommended; controlling lipid levels; quitting smoking; and avoiding alcohol use. Additionally, they recommend regular vaccinations to prevent further complications from diabetes-related illnesses such as pneumococcal pneumonia and influenza.

In addition to lifestyle interventions, there are several medications that can reduce CVD risk in people with Type 2 diabetes. These include statins to lower cholesterol; ACE inhibitors or angiotensin II receptor blockers (ARBs) to manage hypertension; thiazolidinediones or glitazones to improve insulin sensitivity; and glucagon-like peptide 1 (GLP-1) agonists to reduce fasting glucose levels. It is important that patients work closely with their healthcare team when selecting medications to be sure they meet individual needs and goals without causing adverse effects or interactions with other treatments.

Recent evidence-based guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes suggest lifestyle modifications as well as judicious use of pharmacologic therapy to help reduce CVD risk factors in people living with this chronic condition. It is essential that individuals work closely with their healthcare provider in order to develop an effective plan tailored specifically to their needs while maintaining safety standards throughout treatment.

References:

American Diabetes Association (ADA). Standards of medical care in diabetes—2020: Executive summary: Standards of Care 2020 Global Overview [Internet]. Alexandria (VA): ADA; 2020 [cited 7 July 2020]. Available from https://care.diabetesjournals.org/content/43/Supplement_1/S1

National Institutes of Health (NIH). Heart Disease & Stroke Prevention: Type 2 Diabetes [Internet]. Bethesda( MD): NIH; 2017 [updated 21 October 2019; cited 7 July 2020]. Available from https://www.nhlbi.nih

*This article was produced with the assistance of artificial intelligence. Please always check and confirm with your own sources, and always consult with your healthcare professional when seeking medical treatment.